A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of QLS31901 for Injection in Patients With Advanced Malignant Tumors
Latest Information Update: 05 Jun 2023
Price :
$35 *
At a glance
- Drugs QLS 31901 (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors Qilu Pharmaceutical
- 14 Jul 2021 New trial record